Abstract
Ovarian cancer represents one of the major form of cancer in women in the western world and its silent nature leads to a late clinical manifestation at advanced stage in many patients. Therefore the role of imaging techniques is very important for the correct management of these patients. In the present review, the role of 18F-FDG-PET/CT in the different clinical settings is presented and a comparison with other imaging modalities and serum biomarker CA-125 are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 93-102 |
| Number of pages | 10 |
| Journal | Quarterly Journal of Nuclear Medicine and Molecular Imaging |
| Volume | 60 |
| Issue number | 2 |
| Publication status | Published - Jun 1 2016 |
Keywords
- Biomarkers
- Fluorodeoxyglucose F18
- Ovarian neoplasms
- Positron-emission tomography
- Tomography, X-ray computed
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging